Have a feature idea you'd love to see implemented?
Let us know!
XERS Xeris Pharmaceuticals Inc
Price (delayed)
$3.24
Market cap
$482.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$694.96M
Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Highlights
The gross profit has grown by 39% YoY and by 7% from the previous quarter
The company's revenue rose by 35% YoY and by 6% QoQ
XERS's quick ratio is up by 14% year-on-year but it is down by 7% since the previous quarter
XERS's equity has dropped by 110% since the previous quarter
The debt has grown by 20% YoY
Key stats
What are the main financial stats of XERS
Market
Valuations
Earnings
Shares outstanding
149M
Market cap
$482.76M
Enterprise value
$694.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.83
Revenue
$181.41M
EBIT
-$30.22M
EBITDA
-$17.24M
Free cash flow
-$38.83M
Per share
Balance sheet
Liquidity
EPS
-$0.42
Free cash flow per share
-$0.26
Book value per share
-$0.13
Revenue per share
$1.22
TBVPS
$1.38
Total assets
$331.73M
Total liabilities
$351.02M
Debt
$269.8M
Equity
-$19.29M
Working capital
$94.85M
Debt to equity
-13.99
Current ratio
2.26
Quick ratio
1.59
Net debt/EBITDA
-12.31
Margins
Efficiency
Dividend
EBITDA margin
-9.5%
Gross margin
83.7%
Net margin
-32.8%
Operating margin
-20.5%
Return on assets
-18.1%
Return on equity
N/A
Return on invested capital
-9.9%
Return on capital employed
-11.8%
Return on sales
-16.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XERS stock price
How has the Xeris Pharmaceuticals stock price performed over time
Intraday
4.18%
1 week
6.58%
1 month
14.89%
1 year
76.09%
YTD
37.87%
QTD
13.68%
Financial performance
How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$181.41M
Gross profit
$151.88M
Operating income
-$37.19M
Net income
-$59.56M
Gross margin
83.7%
Net margin
-32.8%
Xeris Pharmaceuticals's operating margin has soared by 56% YoY and by 22% from the previous quarter
The operating income has grown by 41% year-on-year and by 17% since the previous quarter
The gross profit has grown by 39% YoY and by 7% from the previous quarter
The net margin has grown by 38% YoY and by 13% from the previous quarter
Growth
What is Xeris Pharmaceuticals's growth rate over time
Valuation
What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.83
XERS's EPS is up by 19% year-on-year and by 9% since the previous quarter
XERS's equity has dropped by 110% since the previous quarter
XERS's price to sales (P/S) is 72% less than its 5-year quarterly average of 9.4 but 47% more than its last 4 quarters average of 1.8
The company's revenue rose by 35% YoY and by 6% QoQ
Efficiency
How efficient is Xeris Pharmaceuticals business performance
The return on invested capital has surged by 58% year-on-year and by 23% since the previous quarter
XERS's ROS has soared by 57% year-on-year and by 24% since the previous quarter
The return on assets rose by 18% year-on-year and by 8% since the previous quarter
Dividends
What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XERS.
Financial health
How did Xeris Pharmaceuticals financials performed over time
The total assets is 5% less than the total liabilities
XERS's current ratio is up by 16% year-on-year but it is down by 4.6% since the previous quarter
XERS's quick ratio is up by 14% year-on-year but it is down by 7% since the previous quarter
The debt to equity has plunged by 185% YoY but it has soared by 52% from the previous quarter
XERS's equity has dropped by 110% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.